Antibody verification of HLA class I and class II eplets by human monoclonal HLA antibodies
HLA · 2024
DOI: 10.1111/tan.15345 ↗Kurz gefasst
Kommentar in der Zeitschrift HLA, 2024. Verfasst von Cynthia S M Kramer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, HLA-DR Antigens. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Reference Center for Histocompatibility Research.
Abstract (Originalsprache)
In solid organ transplantation, formation of de novo donor‐specific HLA antibodies is induced by mismatched eplets on donor HLA molecules. While several studies have shown a strong correlation between the number of eplet mismatches and inferior outcomes, not every eplet mismatch is immunogenic. Eplets are theoretically defined entities, necessitating formal proof that they can be recognised and bound by antibodies. This antibody verification is pivotal to ensure that clinically relevant eplets are considered in studies on molecular matching. Recombinant human HLA‐specific monoclonal antibodies (mAbs) were generated from HLA‐reactive B cell clones isolated from HLA immunised individuals using recombinant HLA molecules. Subsequently, the reactivity patterns of the mAbs obtained from single antigen bead assay were analysed using HLA‐EMMA software to identify single or configurations of solvent accessible amino acids uniquely present on the reactive HLA alleles and were mapped to eplets. Two HLA class I and seven HLA class II‐specific human mAbs were generated from four individuals. Extensive mAb reactivity analysis, led to antibody verification of three HLA‐DR‐specific eplets, and conversion of five eplets (one HLA‐A, one HLA‐B, two HLA‐DR, and one HLA‐DP), from provisionally verified to truly antibody‐verified. Finally, one HLA‐DQ‐specific eplet was upgraded from level A2 to level A1 verification evidence. The generation of recombinant human HLA‐specific mAbs with different specificities contributes significantly to the antibody verification of eplets and therefore is instrumental for implementation of eplet matching in the clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
ORCID-Profile: Cynthia S M Kramer, Suzanne Bezstarosti, Sebastiaan Heidt
Förderung
- National Reference Center for Histocompatibility Research
Zitieren
APA
Kramer, C. S. M., Bezstarosti, S., Franke-van Dijk, M. E. I., Vergunst, M., Roelen, D. L., Uyar-Mercankaya, M., Voogt-Bakker, K. H., & Heidt, S. (2024). Antibody verification of HLA class I and class II eplets by human monoclonal HLA antibodies. HLA. https://doi.org/10.1111/tan.15345
Vancouver
Kramer CSM, Bezstarosti S, Franke-van Dijk MEI, Vergunst M, Roelen DL, Uyar-Mercankaya M, et al. Antibody verification of HLA class I and class II eplets by human monoclonal HLA antibodies. HLA. 2024. doi:10.1111/tan.15345
BibTeX
@article{Kramer2024,
author = {Kramer, Cynthia S M and Bezstarosti, Suzanne and Franke-van Dijk, Marry E I and Vergunst, Manon and Roelen, Dave L and Uyar-Mercankaya, Merve and Voogt-Bakker, Kim H and Heidt, Sebastiaan},
title = {Antibody verification of HLA class I and class II eplets by human monoclonal HLA antibodies},
journal = {HLA},
year = {2024},
doi = {10.1111/tan.15345}
}
EUVIMED